

Uvette Y Lou

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2021914/publications.pdf>

Version: 2024-02-01

11
papers

156
citations

1307594

7
h-index

1372567

10
g-index

11
all docs

11
docs citations

11
times ranked

274
citing authors

#	ARTICLE	IF	CITATIONS
1	Targeting Src-mediated Tyr216 phosphorylation and activation of GSK-3 in prostate cancer cells inhibit prostate cancer progression <i>in vitro</i> and <i>in vivo</i> . <i>Oncotarget</i> , 2014, 5, 775-787.	1.8	53
2	The Incidence, Risk Factors, and Outcomes With 5-Fluorouracil-Associated Coronary Vasospasm. <i>JACC: CardioOncology</i> , 2021, 3, 101-109.	4.0	31
3	Current Treatment Strategies for Multiple Myeloma. <i>JCO Oncology Practice</i> , 2020, 16, 5-14.	2.9	28
4	Overuse and underuse of pegfilgrastim for primary prophylaxis of febrile neutropenia. <i>Journal of Oncology Pharmacy Practice</i> , 2019, 25, 1357-1365.	0.9	10
5	Safety and efficacy of a urine alkalinization protocol developed for high-dose methotrexate patients during intravenous bicarbonate shortage. <i>Journal of Oncology Pharmacy Practice</i> , 2019, 25, 1860-1866.	0.9	10
6	The efficacy and safety of cardio-protective therapy in patients with 5-FU (Fluorouracil)-associated coronary vasospasm. <i>PLoS ONE</i> , 2022, 17, e0265767.	2.5	9
7	Current management and emerging treatment strategies for multiple myeloma. <i>Rinsho Ketsueki/the Japanese Journal of Clinical Hematology</i> , 2019, 60, 1243-1256.	0.5	7
8	Effect of Levetiracetam on Time to High-Dose Methotrexate Clearance in Patients With Hematologic Malignancies. <i>Journal of Clinical Pharmacology</i> , 2020, 60, 324-330.	2.0	5
9	Evaluating the incidence of chemotherapy-induced nausea and vomiting in patients with B-cell lymphoma receiving dose-adjusted EPOCH and rituximab. <i>Journal of Oncology Pharmacy Practice</i> , 2022, 28, 119-126.	0.9	2
10	Associations of sarcopenia with hematologic toxicity, treatment intensity, and healthcare utilization in patients with metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 84-84.	1.6	1
11	Comparison of Denosumab Versus Intravenous (IV) Bisphosphonate Use for Hypercalcemia in Multiple Myeloma. <i>Blood</i> , 2020, 136, 14-16.	1.4	0